138 related articles for article (PubMed ID: 16516696)
1. Urotensin-II levels in acute coronary syndromes.
Joyal D; Huynh T; Aiyar N; Guida B; Douglas S; Giaid A
Int J Cardiol; 2006 Mar; 108(1):31-5. PubMed ID: 16516696
[TBL] [Abstract][Full Text] [Related]
2. The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease.
Heringlake M; Kox T; Uzun O; Will B; Bahlmann L; Klaus S; Eleftheriadis S; Armbruster FP; Franz N; Kraatz E
Regul Pept; 2004 Sep; 121(1-3):129-36. PubMed ID: 15256283
[TBL] [Abstract][Full Text] [Related]
3. Circulating levels of the vasoactive peptide urotensin II in patients with acute coronary syndrome and stable coronary artery disease.
Al Kindi H; Hafiane A; You Z; Albanese I; Pilote L; Genest J; Schwertani A
Peptides; 2014 May; 55():151-7. PubMed ID: 24642358
[TBL] [Abstract][Full Text] [Related]
4. [Clinical study of plasma urotensin II in patients with coronary heart disease].
Fang SH; Li ZL; Wu HC; Tang CS; Lu Q; Liu HC; Yan QN
Di Yi Jun Yi Da Xue Xue Bao; 2004 May; 24(5):563-5. PubMed ID: 15151835
[TBL] [Abstract][Full Text] [Related]
5. Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients.
Oldgren J; James SK; Siegbahn A; Wallentin L
Eur Heart J; 2007 Mar; 28(6):699-704. PubMed ID: 17314110
[TBL] [Abstract][Full Text] [Related]
6. Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes.
Ndrepepa G; Braun S; Mehilli J; von Beckerath N; Schömig A; Kastrati A
Eur J Clin Invest; 2008 Feb; 38(2):90-6. PubMed ID: 18226042
[TBL] [Abstract][Full Text] [Related]
7. TH1/TH2 imbalance, measured by circulating and intracytoplasmic inflammatory cytokines--immunological alterations in acute coronary syndrome and stable coronary artery disease.
Szodoray P; Timar O; Veres K; Der H; Szomjak E; Lakos G; Aleksza M; Nakken B; Szegedi G; Soltesz P
Scand J Immunol; 2006 Sep; 64(3):336-44. PubMed ID: 16918703
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of antibodies to oxidized low-density lipoprotein and assessment of C-reactive protein in acute coronary syndrome and stable coronary artery disease.
Soltesz P; Veres K; Laczik R; Der H; Csipo I; Timar O; Szomjak E; Szegedi G; Szodoray P
Thromb Haemost; 2007 Aug; 98(2):413-9. PubMed ID: 17721625
[TBL] [Abstract][Full Text] [Related]
9. Urotensin-II and cardiovascular remodeling.
Papadopoulos P; Bousette N; Giaid A
Peptides; 2008 May; 29(5):764-9. PubMed ID: 17988761
[TBL] [Abstract][Full Text] [Related]
10. Factor XIa and tissue factor activity in patients with coronary artery disease.
Butenas S; Undas A; Gissel MT; Szuldrzynski K; Zmudka K; Mann KG
Thromb Haemost; 2008 Jan; 99(1):142-9. PubMed ID: 18217146
[TBL] [Abstract][Full Text] [Related]
11. Human urotensin II as a link between hypertension and coronary artery disease.
Watanabe T; Kanome T; Miyazaki A; Katagiri T
Hypertens Res; 2006 Jun; 29(6):375-87. PubMed ID: 16940699
[TBL] [Abstract][Full Text] [Related]
12. API expert consensus document on management of ischemic heart disease.
Association of Physicians of India
J Assoc Physicians India; 2006 Jun; 54():469-80. PubMed ID: 16909697
[TBL] [Abstract][Full Text] [Related]
13. Expression of urotensin-II in human coronary atherosclerosis.
Hassan GS; Douglas SA; Ohlstein EH; Giaid A
Peptides; 2005 Dec; 26(12):2464-72. PubMed ID: 16026900
[TBL] [Abstract][Full Text] [Related]
14. Plasma concentration of SCUBE1, a novel platelet protein, is elevated in patients with acute coronary syndrome and ischemic stroke.
Dai DF; Thajeb P; Tu CF; Chiang FT; Chen CH; Yang RB; Chen JJ
J Am Coll Cardiol; 2008 Jun; 51(22):2173-80. PubMed ID: 18510966
[TBL] [Abstract][Full Text] [Related]
15. Exercise urotensin II dynamics in myocardial infarction survivors with and without hypertension.
Rdzanek A; Filipiak KJ; Karpiński G; Grabowski M; Opolski G
Int J Cardiol; 2006 Jun; 110(2):175-8. PubMed ID: 16198012
[TBL] [Abstract][Full Text] [Related]
16. Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy.
Lapp H; Boerrigter G; Costello-Boerrigter LC; Jaekel K; Scheffold T; Krakau I; Schramm M; Guelker H; Stasch JP
Int J Cardiol; 2004 Mar; 94(1):93-7. PubMed ID: 14996481
[TBL] [Abstract][Full Text] [Related]
17. Plasma urotensin II and neurokinin B levels in acute myocardial infarction and stable coronary artery disease.
Akkoyun DÇ; Akyüz A; Alpsoy Ş; Gürel A; Güler N; Değirmenci H; Gürkan Ü
Anatol J Cardiol; 2015 Aug; 15(8):628-33. PubMed ID: 25550175
[TBL] [Abstract][Full Text] [Related]
18. Low plasma levels of oxygenated carotenoids in patients with coronary artery disease.
Lidebjer C; Leanderson P; Ernerudh J; Jonasson L
Nutr Metab Cardiovasc Dis; 2007 Jul; 17(6):448-56. PubMed ID: 17134954
[TBL] [Abstract][Full Text] [Related]
19. In-hospital outcome of patients with acute coronary syndrome: relationship with inflammation and remodeling markers.
Giansante C; Fiotti N; Di Chiara A; Altamura N; Wasserman S; Fioretti P; Guarnieri G
J Cardiovasc Med (Hagerstown); 2007 Aug; 8(8):602-7. PubMed ID: 17667031
[TBL] [Abstract][Full Text] [Related]
20. Regulation of platelet glycoprotein VI (GPVI) surface expression and of soluble GPVI in patients with atrial fibrillation (AF) and acute coronary syndrome (ACS).
Bigalke B; Stellos K; Weig HJ; Geisler T; Seizer P; Kremmer E; Pötz O; Joos T; May AE; Lindemann S; Gawaz M
Basic Res Cardiol; 2009 May; 104(3):352-7. PubMed ID: 19190951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
